Eric Wu

Inhibition of fatty acid synthase with <scp>FT‐4101</scp> safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials

Carine Beysen, Patricia Schroeder, Eric Wu et al. · Diabetes Obesity and Metabolism · 2020 · 53 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Association of Gastroesophageal Reflux With Malignancy of the Upper Aerodigestive Tract in Elderly Patients

Charles A. Riley, Eric Wu, Mei‐Chin Hsieh et al. · JAMA Otolaryngology–Head & Neck Surgery · 2017 · 36 citations · Full text

Medicine, Internal Medicine, Oncology +14

Cross-species complementation of the indispensable Escherichia coli era gene highlights amino acid regions essential for activity

Renuka Pillutla, J. Daniel Sharer, P. Gulati et al. · Journal of Bacteriology · 1995 · 33 citations · Full text

Life Sciences, Genetics, Microbiology +9

Chronic sinonasal tract inflammation as a precursor to nasopharyngeal carcinoma and sinonasal malignancy in the United States

Eric Wu, Charles A. Riley, Mei‐Chin Hsieh et al. · International Forum of Allergy & Rhinology · 2017 · 32 citations

Medicine, Oncology, Otolaryngology +15

Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial

Sanjeev Forsyth, Patricia Schroeder, James Geib et al. · Clinical Pharmacology in Drug Development · 2022 · 31 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10